Mitoxantrone hydrochloride

CAS No. 70476-82-3

Mitoxantrone hydrochloride( NCI 301739 | Novantrone | NSC 301739 )

Catalog No. M15709 CAS No. 70476-82-3

Mitoxantrone Dihydrochloride, a type II topoisomerase inhibitor, is an anthracenedione-derived antineoplastic agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 45 In Stock
100MG 65 In Stock
500MG 165 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Mitoxantrone hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Mitoxantrone Dihydrochloride, a type II topoisomerase inhibitor, is an anthracenedione-derived antineoplastic agent.
  • Description
    Mitoxantrone Dihydrochloride, a type II topoisomerase inhibitor, is an anthracenedione-derived antineoplastic agent.(In Vitro):Mitoxantrone dihydrochloride inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP.Mitoxantrone dihydrochloride (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone dihydrochloride induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone dihydrochloride is due to induction of apoptosis.Mitoxantrone dihydrochloride shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively.(In Vivo):Mitoxantrone dihydrochloride (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia.Mitoxantrone dihydrochloride (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma.
  • In Vitro
    Mitoxantrone dihydrochloride inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP.Mitoxantrone dihydrochloride (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone dihydrochloride induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone dihydrochloride is due to induction of apoptosis.Mitoxantrone dihydrochloride shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively.
  • In Vivo
    Mitoxantrone dihydrochloride (IP, 0-3.2 mg/kg/day) produces a statistically significant number of 60-day survivors at 1.6 mg/kg in mice with IP implanted L1210 leukemia.Mitoxantrone dihydrochloride (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma.
  • Synonyms
    NCI 301739 | Novantrone | NSC 301739
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Topoisomerase
  • Recptor
    Topo II
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    70476-82-3
  • Formula Weight
    517.4
  • Molecular Formula
    C22H30Cl2N4O6
  • Purity
    >98% (HPLC)
  • Solubility
    Water: 89 mg/mL (172.01 mM); DMSO: 89 mg/mL (172.01 mM)
  • SMILES
    Cl.Cl.OCCNCCNC1=C2C(=O)C3=C(O)C=CC(O)=C3C(=O)C2=C(NCCNCCO)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Seitz M. Curr Opin Rheumatol, 1999, 11(3), 226-232.
molnova catalog
related products
  • Wogonoside

    Wogonoside acts as a?positive allosteric modulator?of the?benzodiazepine site of the?GABAA?receptor.

  • DRF-1042

    DRF-1042, an orally active camptothecin analog, exhibits anticancer and insecticidal activities by inhibiting DNA topoisomerase I. It has been studied for its efficacy against solid tumors, including prostate and colon cancers.

  • MC-DOXHZN

    MC-DOXHZN is an albumin-binding prodrug of Doxorubicin (DNA topoisomerase II inhibitor), with acid-sensitive properties.